Candel Therapeutics Acquires Next-Generation Herpes Drug Development Platform and Manufacturing Expertise
Jan 8, 2020
NEEDHAM, Mass., Jan. 8, 2020 /PRNewswire/ -- Candel Therapeutics, a leader in developing viral immunotherapies across multiple tumor indications, announced today that it has acquired all oncolytic and other Herpes Simplex Virus (HSV) based assets from PeriphaGen, Inc., bringing its vector engineering, production expertise and next-generation HSV drug development platform in-house. This acquisition solidifies Candel's viral therapy leadership position and supports further development of Candel's rQNestin34.5, currently in a Phase 1 study for recurrent malignant gliomas. Terms of the transaction were not disclosed.
The acquired development platform enables precise modifications to the virus backbone, allowing customization of viral traits such as replication capacity, tissue specificity and expression of a large number of payloads including immunomodulators. With Candel's expertise, the new platform will support the rapid generation of drug candidates that can be tailored to a range of indications and tumor types.
In addition, Candel acquired PeriphaGen's lead product candidate developed to address chemotherapy induced peripheral neuropathy. This product candidate has been rationally engineered to provide neuroprotective activity via high-level and durable expression of a neurotrophin peptide to specific impacted nerve ganglia. PeriphaGen's two scientific founders, highly respected experts in Herpes vectorology and peripheral neuropathy, David Krisky, M.D., Ph.D. and James Wechuck, Ph.D, have joined Candel to support the seamless integration and continuous development of the platform and products.
"The acquisition of PeriphaGen's platform is highly complementary to Candel's strategy, accelerating our drug development and manufacturing capabilities to advance innovative HSV gene therapy products," said Dr. Estuardo Aguilar Cordova, CEO of Candel. "With this transaction, we further strengthen our position as one of the most advanced companies in the viral therapeutic space."
About Candel Therapeutics
Advantagene, Inc. d.b.a. Candel Therapeutics is a Needham, Massachusetts based biotechnology company developing its proprietary immuno-oncology platforms, including its Gene Mediated Cytotoxic Immunotherapy (GMCI™) and proprietary HSV based platform, for the treatment of solid tumors and associated neurological pathologies.
For more information about our clinical programs, please visit www.clinicaltrials.gov or click the following link: https://clinicaltrials.gov/ct2/results?cond=&term=advantagene&cntry=&state=&city=&dist=
Media contact:
Stephen Rocamboli
[email protected]
917-620-2256
SOURCE Candel Therapeutics
More News
What can I do to protect myself after 'Asos hacked' message?
Asos says people should not engage with the unauthorised notification and says it'll provide further information.
These Taste Testers Have Four Legs and Picky Palates
Global pet food makers chasing a growing market are pouring big money into studying the taste buds of dogs and cats.
Amazon wins global rights to stream Emmys in six-year deal
The gala is leaving traditional US broadcast networks for live worldwide streaming.
From films to streaming prices - how the Warner Bros deal could affect you
The deal is expected to alter the entertainment and news industries but could it mean higher prices for consumers?
A.I. Officials Stonewall on Questions About Technology’s Risks
A New York City Council hearing on artificial intelligence yielded few answers or assurances about how the industry would provide safeguards against catastrophic scenarios.
Asos confirms hackers sent 'unauthorised' notification to app users
Asos confirmed an "unauthorised customer notification" was sent out via its app on Tuesday, after users raised alarm.
‘Digger,’ Warner Bros.’ Last Release Before Merger, Is a Major Flop
The film, starring Tom Cruise, grossed an estimated $8 million in its opening weekend. That could put the movie on track to lose at least $125 million.
Roll-out begins for passport-free airport e-gates
The system uses facial technology to check travellers against immigration and passport information.
Emmy Awards Move to Prime Video in Six-Year Deal With Amazon
The Television Academy is moving its awards telecast to streaming, following the lead of the Oscars.
Trump Allows Cheaper, Dyed Diesel to Be Used in Nonfarm Vehicles
In Nebraska, President Trump signed an executive order to waive an off-road requirement for the fuel, which is exempt from the federal highway tax.
U.S. Trade Deficit Hits 17-Month High Despite Trump’s Tariffs
Imports and the trade deficit have ballooned in recent months, defying the Trump administration’s efforts to reduce it through tariffs.
NHS supply lorry drivers to strike in pay dispute
Drivers who deliver medical equipment to hospitals across England reject a 4% pay increase.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.